The aim of the trial is to fully understand the benefits of a PARP inhibitor versus standard chemotherapy for BRCA positive women who have had two previous treatments. It is a three arm trial, where women will be randomised to receive:
The Clinical Trials Information Centre aims to give you information about what clinical trials are taking place that you may be eligible for. The search function below allows you to search by your location, your treatment stage and the stage of the trial. If you find a trial you think you may be eligible for, we suggest you print the information to take along to your next appointment with your clinical team as you will not be able to join the trial without the support of your clinical team.
In addition to the larger trials taking place in centres across the UK, there are sometimes phase I trials which have an even stricter entry criteria. We have not listed all of these but have instead listed where the phase I centres are so that you can ask your clinical team to contact them to find out if there’s any trials you may be eligible for.
This site will be updated regularly as trials are opening and closing in different locations all the time. Whilst we endeavour to keep it as up to date as we can, please always check with your clinical team about the availability of a trial in your area.
If you are confused about some of the terms and language used in the trial descriptions, use our glossary of terms used in clinical trials.
If you have any queries about the clinical trials information centre, you can call the Target Ovarian Cancer support line on 020 7923 5475 or email support@targetovariancancer.org.uk
Results list
This trial is a randomised, double-blind, placebo-controlled four-arm, Phase-3 clinical trial. This means the participant is randomly (by chance) assigned by a computer program to one of 4 possible study drug combinations (“four arm”) which involve rucaparib or matching placebo twice daily and nivolumab or placebo IV infusion approximately every 4 weeks.
The main purpose of the trial is to assess the safety of combining two medicines, cediranib with paclitaxel, and how well the treatment works in terms of shrinking the cancer and preventing bowel obstruction.
Three different medicines are being tested as part of the treatment:
Paclitaxel, a standard chemotherapy drug given as a weekly infusion.
An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma).
An elemental diet is a type of a drink that is already digested so that the body does not need to do any work. It contains energy, broken-down proteins, vitamins and minerals. Elemental drinks are almost totally absorbed in the upper part of the bowel and therefore could be absorbed even in patients who have bowel blockage lower down in the gut.
This study tests a new drug both in combination with a known treatment and alone, in advanced platinum-resistant ovarian cancer.
Atezolizumab (the new drug) is an ‘immunotherapy’ drug that boosts your body's own immune system in a way that may slow down or stop tumour growth.
Bevacizumab, (the known drug), already used against this disease, and given in combination with chemotherapy, is a drug that stops the tumour from growing its own blood vessels, which in turn should slow the growth of the tumour itself.
This study will follow a large group of patients over time who have had a diagnosis of cancer. Participants will be asked to complete questionnaires to find out how people’s health and wellbeing is after diagnosis and treatment. This information will help in the understanding of the impact that cancer diagnosis and treatment has on everyday life. Recruitment will take place prior to treatment from hospitals across the UK.
Women will be randomised into two groups:
Group B1
Women in this group will receive 18 weeks of:
Carboplatin once every three weeks
Paclitaxel once every three weeks
Bevacizumab once every three weeks followed by bevacizumab continuing alone for approximately 11 months
Group B3
Women in this group will receive 18 weeks of:
ICON9 is a randomised study and patients will be randomly allocated to receive one or both of the anti-cancer drugs on completion of their chemotherapy (called maintenance treatment). Patients will be in the study for up to 6 years and will continue taking the study tablets until their study doctor thinks they are no longer helping to control the disease. Study tablets may also be discontinued by the study doctor if patients experience side effects that have a negative impact on their quality of life.
PARP inhibitors, such as olaparib, significantly improve progression free survival (PFS) in participants with recurrent, platinum-sensitive high-grade serous/endometrioid ovarian cancer (HGS/EOC), who have a mutation in BRCA 1 or 2 genes. The investigators will test the feasibility of administering a second course of olaparib in participants who have recurrent platinum-sensitive HGS/EOC.
Surgery is the usual treatment for ovarian cancer. A CT scan is used to check where the cancer is in the body and helps doctors to know if surgery would be a suitable treatment choice. However, sometimes the CT scan can’t:
Women will be randomised to one of three treatment groups:
Paclitaxel – weekly intravenously
Olaparib – taken orally, twice daily
Olaparib and cediranib – taken orally, twice daily and once daily respectively
The main purpose of this study is to see if Olaparib (study drug) re-treatment is effective in participants with ovarian cancer, who have already been treated with Olaparib or similar drugs.
Olaparib is an oral treatment that is taken at home every day. A tablet formulation of olaparib is being tested in this study. It is a new formulation which is more convenient for participants than the approved capsule formulation because fewer tablets of olaparib need to be taken daily than with capsules.
All women in the study will receive the study drug, pembrolizumab, for up to 2 years or until their study doctor thinks the study drug is no longer helping to control the cancer or if unacceptable side effects are seen or if the woman wishes to stop treatment.
Some women may also be suitable for a possible retreatment period with pembrolizumab for up to 1 year, if the cancer starts growing again.
Find out about phase I clinical trials available for women with ovarian cancer.
It is now well established that a large proportion of ovarian cancers start in the tube. A number of experts believe that removing the tubes alone would provide some protection from getting ovarian cancer This ‘first stage’ is called risk reducing early salpingectomy (RRES). (Salpingectomy = removal of tubes). This may be particularly helpful for those women who wish to avoid or delay menopause. Women who just have their fallopian tubes removed will need to have a second operation at a later date to remove their ovaries.
The purpose of this study is to obtain more information about specific rare gynaecological cancers. Gynaecological oncology doctors have selected approximately 20 gynaecological cancers that are very uncommon (probably between 5 and 50 new cases in the UK per year per rare cancer type). The information from the study will help doctors to better understand how these rare cancers are diagnosed and managed at present so that in the future they can be more confident about what treatments to offer patients.
The trial offers a genetic test to women with certain types of ovarian cancer. This is to detect gene alterations that may be a cause of ovarian cancer. The test will look for alterations in the following genes: BRCA1, BRCA2, RAD51C, RAD51D and BRIP1. At present, testing for changes in the genes BRCA1 and BRCA2 is standard practice. However, testing for the additional genes (RAD51C, RAD51D, BRIP1) is limited to a small number of units.
To compare the overall survival (OS) after primary debulking surgery (PDS) versus interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) in patients with FIGO (2014) stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma.